AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 21 min read$CLX

Clorox: Matthew J. Shattock acquires 648 stock units

Clorox director Matthew J. Shattock acquired 648.0681 Deferred Stock Units on September 30, 2026, and 255.3782 units on August 28, 2026, through dividend reinvestment. These units will be settled in Clorox stock upon his retirement or termination of service.

Original reporting
stocktitan.net
Published Oct 2, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CLX
Neutral
high confidence
Mentioned
$CLX
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLXNeutralLow
01

Why it matters

The filing is a routine insider compensation disclosure with no immediate financial impact.

02

Market read

A routine Form 4 filing with negligible trading relevance.

03

What to watch

The grant could align director incentives with shareholders, but the impact remains marginal.

Relevance 4/10Novelty 4/10Timing: same-day filing

Background

Clorox's Independent Directors' Deferred Compensation Plan allows directors to receive deferred stock units in lieu of cash fees, settled in stock upon retirement or termination.

Company-level read

Ticker impact

$CLXNeutralHigh confidence
Context

Clorox disclosed a Form 4 granting director Matthew J. Shattock 648.07 deferred stock units and 255.38 units via dividend reinvestment.

Expected impact

likely negligible pressure as the market prices in the non‑dilutive grant.

Evidence & confidence

The grant involves no cash outlay and a modest number of units, typical for director compensation, offering no material upside or downside.

Market effects

Sector

None; the filing is specific to Clorox and does not affect the broader consumer‑goods sector.

Regional

None; limited to US investors in CLX.

Global

Minimal; no global market effect.

Counterpoint

What could challenge this read

Even small insider grants can signal confidence; some traders may view this as a subtle bullish cue.

Key entities

  • company
    Clorox Co.

    US consumer‑goods company (ticker CLX).

  • person
    Matthew J. Shattock

    Director of Clorox receiving deferred stock units.

Read at source← All news

Related articles

SEP 3
$CLXMed

Can Cost Savings Offset Inflation & Protect Clorox's Margins?

Clorox (CLX) reported a 520 basis point gross margin contraction in Q4 fiscal 2026 due to inflation and mix challenges. The company is focusing on cost savings and productivity initiatives to offset inflationary pressures, but expects margins to remain pressured in fiscal 2027. CLX shares have risen 5.2% in the past three months, with a forward P/E of 15.97X.

finance.yahoo.com2 min
AUG 21
$CLXMedAI 8/10

How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook

Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.

tradingview.com3 min
AUG 21
$CLXMedAI 8/10

Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure?

Clorox (CLX) reports Q4 net sales of $1.95B, up 2% YoY, with GOJO contributing 10 percentage points. Fiscal 2027 sales expected to rise 13-14%, with adjusted EPS at $5.70-$6.00. Gross margins declined due to inflation and higher costs. Organic sales growth is muted, with ERP comparisons aiding growth. CLX trades at 17.9X forward earnings, below its sub-industry multiple.

tradingview.com3 min
AUG 14
$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

yahoo.com6 min
AUG 11
$CLXMedAI 8/10

Clorox (CLX) Q4 2026 Earnings Call Transcript

Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.

fool.com6 min
AUG 6
$CLXMed

The Clorox Company Q4 2026 Earnings Call Summary

Clorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.

yahoo.com7 min